(Total Views: 504)
Posted On: 10/16/2020 12:11:11 AM
Post# of 153832
Re: Borel Fields #61317
It could be OncoImmune was so close to full enrollment they decided to hold off for full trial results.
The effect of OncoImmune's drug is NF-kB inhibition and they had great results. Leronlimab also inhibits NF-kB and does more.
The effect of OncoImmune's drug is NF-kB inhibition and they had great results. Leronlimab also inhibits NF-kB and does more.
(0)
(0)
